Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first‑line treatment of metastatic colorectal cancer

Varol,Umut; Oktay,Esin; Yildirim,Mustafa; Surmeli,Zeki  Gokhan; Dirican,Ahmet; Meydan,Nezih; Karaca,Burcak; Karabulut,Bulent; Uslu,Ruchan

doi:10.3892/mco.2013.212

Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first‑line treatment of metastatic colorectal cancer

Authors:
- Umut Varol
- Esin Oktay
- Mustafa Yildirim
- Zeki Gokhan Surmeli
- Ahmet Dirican
- Nezih Meydan
- Burcak Karaca
- Bulent Karabulut
- Ruchan Uslu
View Affiliations

Affiliations: Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Ege University, Bornova/Izmir, Turkey, Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey, Department of Medical Oncology, Antalya Research and Training Hospital, Antalya, Turkey, Department of Medical Oncology, Izmir Ataturk Research and Training Hospital, Izmir, Turkey
Published online on: November 12, 2013 https://doi.org/10.3892/mco.2013.212
Pages: 166-170

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is among the most frequently diagnosed cancers and a major cause of cancer‑related mortality worldwide. The aim of the present study was to determine whether there was an improvement in the time to disease progression (TTP) in patients with metastatic colorectal cancer (mCRC) treated with first‑line bevacizumab plus chemotherapy, according to tumor characteristics and metastatic sites. Tumor characteristics and tumor burden were considered to be predictive markers of the therapeutic efficacy of bevacizumab. The medical records of 705 patients with mCRC were retrospectively reviewed in three oncology centers between January, 2005 and September, 2012. A total of 101 patients completed their first‑line bevacizumab‑containing treatment. The median TTP was 6.93 months [interquartile range (IQR)=4.20‑9.80 months] in patients treated with irinotecan, 5‑fluorouracil (5‑FU) and bevacizumab vs. 7.42 months (IQR=6.08‑10.68 months) in those treated with oxaliplatin, 5‑FU and bevacizumab (P=0.589). When we compared patients with pulmonary metastases (median TTP, 9.9000 months) or other metastatic patients without pulmonary metastasis (median TTP, 6.9000 months), we observed a statistically significant difference (P=0.046). However, when the efficacy of bevacizumab was compared in terms of other tumor characteristics (tumor grade, size and lymph node involvement) and metastatic sites, the differences were not significant (P>0.05). We concluded that bevacizumab may be effective in all subgroups of patients with mCRC. Furthermore, bevacizumab with combination chemotherapy may be superior to combination chemotherapy only as the first‑line treatment of patients with mCRC and pulmonary metastasis.

View Figures

View References

1.	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2.	de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 18:2938–2947. 2000.
3.	Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 25:4779–4786. 2007. View Article : Google Scholar
4.	Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 22:23–30. 2004. View Article : Google Scholar
5.	Chaudhury P, Hassanain M, Bouganim N, et al: Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB (Oxford). 12:37–42. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Sobrero AF, Maurel J, Fehrenbacher L, et al: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 26:2311–2319. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R and Ramírez-Márquez M: Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D. 11:101–111. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Strickler JH and Hurwitz HI: Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist. 17:513–524. 2012. View Article : Google Scholar : PubMed/NCBI
9.	Chibaudel B, Tournigand C, André T and de Gramont A: Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol. 4:75–89. 2012. View Article : Google Scholar : PubMed/NCBI
10.	De Stefano A, Carlomagno C, Pepe S, et al: Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol. 68:1207–1213. 2011.PubMed/NCBI
11.	Pohl A, El-Khoueiry A, Yang D, et al: Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J. 13:173–180. 2013. View Article : Google Scholar : PubMed/NCBI
12.	Sastre J, Maestro ML, Gómez-España A, et al: Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist. 17:947–955. 2012. View Article : Google Scholar
13.	Formica V, Palmirotta R, Del Monte G, et al: Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis. 26:143–151. 2011. View Article : Google Scholar
14.	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
15.	Gervaz P, Scholl B, Mainguene C, et al: Angiogenesis of liver metastases: role of sinusoidal endothelial cells. Dis Colon Rectum. 43:980–986. 2000. View Article : Google Scholar : PubMed/NCBI
16.	Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with meta-static colorectal cancer. J Clin Oncol. 21:60–65. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Des Guetz G, Uzzan B, Nicolas P, et al: Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 94:1823–1832. 2006.PubMed/NCBI
18.	Degirmenci M, Karaca B, Gorumlu G, et al: Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Med Oncol. 27:585–591. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
20.	Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
21.	Vredenburgh JJ, Desjardins A, Herndon JE Jr, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 25:4722–4729. 2007. View Article : Google Scholar : PubMed/NCBI
22.	Scartozzi M, Giampieri R, Maccaroni E, et al: Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer. 106:799–804. 2012. View Article : Google Scholar
23.	Hong YS, Cho HJ, Kim SY, et al: Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer. 9:2462009. View Article : Google Scholar : PubMed/NCBI
24.	Suenaga M, Matsusaka S, Ueno M, et al: Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in meta-static colorectal cancer patients. Surg Today. 41:1067–1074. 2011. View Article : Google Scholar : PubMed/NCBI
25.	Formica V, Massara MC, Portarena I, et al: Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Cancer Biomark. 5:167–175. 2009.PubMed/NCBI
26.	Guiu B, Petit JM, Bonnetain F, et al: Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut. 59:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
27.	Budai B, Komlósi V, Adleff V, et al: Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab. Pharmacogenet Genomics. 22:69–72. 2012.PubMed/NCBI
28.	Abajo A, Rodriguez J, Bitarte N, et al: Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. Br J Cancer. 103:1529–1535. 2010. View Article : Google Scholar
29.	Hansen TF, Christensen Rd, Andersen RF, et al: The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. Int J Colorectal Dis. 27:715–720. 2012. View Article : Google Scholar
30.	Colucci G, Gebbia V, Paoletti G, et al Gruppo Oncologico Dell’Italia Meridionale: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol. 23:4866–4875. 2005.PubMed/NCBI
31.	Abajo A, Boni V, Lopez I, et al: Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. Br J Cancer. 107:287–290. 2012. View Article : Google Scholar